Drugs / SCRI-CAR19v3
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06465147 | Dec 2024 → Oct 2028 expected | systemic lupus erythematosus | Seattle Children's Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SCRI-CAR19v3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06465147 ↗ |
| Modality | Cell therapy | “The T cells will then be bioengineered into a CAR T cell” NCT06465147 ↗ |
| Target | CD19 | “genetically modified to express CD19 specific chimeric antigen receptor (CAR)” NCT06465147 ↗ |